Results 131 to 140 of about 12,338 (219)
Internal Medicine Journal, EarlyView.Abstract Idiopathic multicentric Castleman disease (iMCD) is a rare condition. The pathogenesis is incompletely understood; however, interleukin‐6 (IL‐6) is a major mediator. The clinical presentation is heterogeneous, from mild constitutional symptoms to severe multi‐organ failure.
Dipti Talaulikar +16 more
wiley +1 more source
Bortezomib-induced NF-κB activation.
, 2012 Su-DHL8 cells were treated with 20 nM bortezomib with or without 50 µg/ml of CQ. (A and B) Effects of bortezomib or/and CQ on the levels of NF-κB proteins. Cytosolic and nuclear proteins were extracted from Su-DHL8 cells.
Ganga Gopinathan (181205) +3 more
core +1 more source
Transplant Infectious Disease, EarlyView.During the 2023–2024 Argentine dengue outbreak, 33 patients with hematological disease showed high complication rates, frequent hospitalization (64%), severe thrombocytopenia (90%), and 6% dengue‐attributable mortality. Transfusion‐associated cases were documented.
Gustavo Adolfo Méndez +16 more
wiley +1 more source
Bortezomib for Refractory Autoimmunity in Pediatrics
, 2014 Therapy of refractory autoimmunity remains challenging. In this study, we evaluated the therapeutic effect of bortezomib, a proteasome inhibitor, by targeting plasma cells in 7 patients (median age, 9.9 years).
Davies, Stella M. +15 more
core +1 more source
Dihydrolipoamide dehydrogenase (DLD) is a novel molecular target of bortezomib
Cell Death and DiseaseProteasome inhibitors (PIs), such as bortezomib and calfizomib, were backbone agents in the treatment of multiple myeloma (MM). In this study, we investigated bortezomib interactors in MM cells and identified dihydrolipoamide dehydrogenase (DLD) as a ...
Yu Feng +14 more
doaj +1 more source
International Journal of Cancer, Volume 159, Issue 2, Page 460-466, 15 July 2026.What's new? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins +3 more
wiley +1 more source
Cost-effectiveness of bortezomib for multiple myeloma: a systematic review
, 2016 Wendong Chen,1 Yicheng Yang,2 Yi Chen,3 Fen Du,3 Huan Zhan3 1Normin Health, Toronto, ON, Canada; 2Xian Janssen, Beijing, People's Republic of China; 3Normin Health Changsha Representative Office, Changsha, People's Republic of China Objectives ...
Yang Y, Du F, Chen W, Zhan H, Chen Y
core
American Journal of Hematology, Volume 101, Issue 7, Page 1433-1439, July 2026.ABSTRACT Patients with relapsed/refractory multiple myeloma (RRMM) who are penta‐drug refractory, defined as resistant to two proteasome inhibitors, two immunomodulatory agents, and an anti‐CD38 monoclonal antibody, face a dismal prognosis, particularly after exposure to T‐cell–redirecting therapies.
Maximilian Al‐Bazaz +22 more
wiley +1 more source
American Journal of Hematology, Volume 101, Issue 7, Page 1597-1604, July 2026.ABSTRACT Sutimlimab is a monoclonal antibody against complement fraction C1s approved for the treatment of hemolytic anemia due to cold agglutinin disease (CAD). Here, we analyzed and report the largest international CAD cohort of sutimlimab‐treated patients ever reported to highlight its safety and effectiveness in the real‐world setting. We accrued a
Bruno Fattizzo +38 more
wiley +1 more source
American Journal of Hematology, Volume 101, Issue 7, Page 1484-1493, July 2026.ABSTRACT Renal impairment (RI), defined as estimated glomerular filtration rate less than 60 mL/min with or without the need for dialysis, is a frequent and severe complication in patients with relapsed/refractory multiple myeloma (RRMM), as it can affect patient prognosis, drug metabolism and treatment options.
Ioannis Ntanasis‐Stathopoulos +7 more
wiley +1 more source